469 related articles for article (PubMed ID: 33975059)
1. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
Gan CL; Stukalin I; Meyers DE; Dudani S; Grosjean HAI; Dolter S; Ewanchuk BW; Goutam S; Sander M; Wells C; Pabani A; Cheng T; Monzon J; Morris D; Basappa NS; Pal SK; Wood LA; Donskov F; Choueiri TK; Heng DYC
Eur J Cancer; 2021 Jul; 151():115-125. PubMed ID: 33975059
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.
Heng DY; Choueiri TK; Rini BI; Lee J; Yuasa T; Pal SK; Srinivas S; Bjarnason GA; Knox JJ; Mackenzie M; Vaishampayan UN; Tan MH; Rha SY; Donskov F; Agarwal N; Kollmannsberger C; North S; Wood LA
Ann Oncol; 2014 Jan; 25(1):149-54. PubMed ID: 24356626
[TBL] [Abstract][Full Text] [Related]
3. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
Basak EA; van der Meer JWM; Hurkmans DP; Schreurs MWJ; Oomen-de Hoop E; van der Veldt AAM; Bins S; Joosse A; Koolen SLW; Debets R; Peeters RP; Aerts JGJV; Mathijssen RHJ; Medici M
Thyroid; 2020 Jul; 30(7):966-973. PubMed ID: 32151195
[No Abstract] [Full Text] [Related]
4. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Santoni M; Buti S; Myint ZW; Maruzzo M; Iacovelli R; Pichler M; Kopecky J; Kucharz J; Rizzo M; Galli L; Büttner T; De Giorgi U; Kanesvaran R; Fiala O; Grande E; Zucali PA; Kopp RM; Fornarini G; Bourlon MT; Scagliarini S; Molina-Cerrillo J; Aurilio G; Matrana MR; Pichler R; Cattrini C; Büchler T; Massari F; Seront E; Calabrò F; Pinto A; Berardi R; Zgura A; Mammone G; Ansari J; Atzori F; Chiari R; Bamias A; Caffo O; Procopio G; Sunela K; Bassanelli M; Ortega C; Grillone F; Landmesser J; Milella M; Messina C; Küronya Z; Mosca A; Bhuva D; Santini D; Vau N; Morelli F; Incorvaia L; Rebuzzi SE; Roviello G; Soares A; Bisonni R; Bimbatti D; Zabalza IO; Rizzo A; Mollica V; Sorgentoni G; Monteiro FSM; Battelli N; Bracarda S; Porta C
Eur Urol Oncol; 2024 Feb; 7(1):102-111. PubMed ID: 37481365
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
6. Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers.
Parikh RB; Min EJ; Wileyto EP; Riaz F; Gross CP; Cohen RB; Hubbard RA; Long Q; Mamtani R
JAMA Oncol; 2021 Dec; 7(12):1843-1850. PubMed ID: 34734979
[TBL] [Abstract][Full Text] [Related]
7. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
[TBL] [Abstract][Full Text] [Related]
8. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Gan CL; Dudani S; Wells JC; Donskov F; Pal SK; Dizman N; Rathi N; Beuselinck B; Yan F; Lalani AA; Hansen A; Szabados B; de Velasco G; Tran B; Lee JL; Vaishampayan UN; Bjarnason GA; Subasri M; Choueiri TK; Heng DYC
Cancer Med; 2021 Feb; 10(4):1212-1221. PubMed ID: 33463028
[TBL] [Abstract][Full Text] [Related]
9. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma.
Ernst MS; Navani V; Wells JC; Donskov F; Basappa N; Labaki C; Pal SK; Meza L; Wood LA; Ernst DS; Szabados B; McKay RR; Parnis F; Suarez C; Yuasa T; Lalani AK; Alva A; Bjarnason GA; Choueiri TK; Heng DYC
Eur Urol; 2023 Jul; 84(1):109-116. PubMed ID: 36707357
[TBL] [Abstract][Full Text] [Related]
10. Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials-Analyses From the German Clinical RCC Registry.
Marschner N; Staehler M; Müller L; Nusch A; Harde J; Koska M; Jänicke M; Goebell PJ;
Clin Genitourin Cancer; 2017 Apr; 15(2):e209-e215. PubMed ID: 27720164
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors.
Graham J; Shah AY; Wells JC; McKay RR; Vaishampayan U; Hansen A; Donskov F; Bjarnason GA; Beuselinck B; De Velasco G; Iafolla M; Duh MS; Huynh L; Chang R; Zanotti G; Ramaswamy K; Choueiri TK; Tannir NM; Heng DYC
Eur Urol Oncol; 2021 Feb; 4(1):102-111. PubMed ID: 31786162
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics and Prognosis of Patients With Advanced Non-Small-cell Lung Cancer Who Are Ineligible for Clinical Trials.
Kawachi H; Fujimoto D; Morimoto T; Ito M; Teraoka S; Sato Y; Nagata K; Nakagawa A; Otsuka K; Tomii K
Clin Lung Cancer; 2018 Sep; 19(5):e721-e734. PubMed ID: 29934133
[TBL] [Abstract][Full Text] [Related]
13. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies.
Sawaya GB; Dragomir A; Wood LA; Kollmannsberger C; Basappa NS; Kapoor A; Soulières D; Finelli A; Heng DYC; Castonguay V; Canil C; Winquist E; Graham J; Bjarnason GA; Bhindi B; Lalani AK; Pouliot F; Breau RH; Saleh R; Tanguay S
Eur Urol Oncol; 2024 Jun; 7(3):570-580. PubMed ID: 38097481
[TBL] [Abstract][Full Text] [Related]
14. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials.
O'Connor JM; Fessele KL; Steiner J; Seidl-Rathkopf K; Carson KR; Nussbaum NC; Yin ES; Adelson KB; Presley CJ; Chiang AC; Ross JS; Abernethy AP; Gross CP
JAMA Oncol; 2018 Aug; 4(8):e180798. PubMed ID: 29800974
[TBL] [Abstract][Full Text] [Related]
15. Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer.
Yoo SH; Keam B; Kim M; Kim TM; Kim DW; Heo DS
Thorac Cancer; 2018 Jun; 9(6):736-744. PubMed ID: 29682899
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7).
Santini D; Stellato M; De Giorgi U; Pantano F; De Lisi D; Casadei C; Maruzzo M; Bimbatti D; Naglieri E; Buti S; Bersanelli M; De Vivo R; Di Lorenzo G; Sbrana A; Verzoni E; Soraru' M; Fornarini G; Mucciarini C; Grillone F; Mini E; Vignani F; Attademo L; Pignata S; Procopio G
Am J Clin Oncol; 2021 Mar; 44(3):121-125. PubMed ID: 33617179
[TBL] [Abstract][Full Text] [Related]
17. Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
Sukari A; Nagasaka M; Alhasan R; Patel D; Wozniak A; Ramchandren R; Vaishampayan U; Weise A; Flaherty L; Jang H; Kim S; Gadgeel S
Anticancer Res; 2019 Feb; 39(2):781-790. PubMed ID: 30711957
[TBL] [Abstract][Full Text] [Related]
18. Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.
Park R; Lopes L; Saeed A
Clin Transl Oncol; 2021 Jan; 23(1):100-109. PubMed ID: 32495269
[TBL] [Abstract][Full Text] [Related]
19. Real-world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy.
Goldschmidt JH; Chou LN; Chan PK; Chen L; Robert N; Kinsey J; Pitts K; Nestor M; Rock EP; Lazarus HM
Cancer Med; 2023 Nov; 12(22):20783-20797. PubMed ID: 37962239
[TBL] [Abstract][Full Text] [Related]
20. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
Noronha V; Abraham G; Patil V; Joshi A; Menon N; Mahajan A; Janu A; Jain S; Talreja VT; Kapoor A; Kumar Singh G; Khaddar S; Gupta K; Rathinasamy N; Srinivas S; Agrawal A; Ventrapati P; Prabhash K
Cancer Med; 2021 Mar; 10(5):1525-1534. PubMed ID: 33591635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
